Cargando…

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients

Only a few studies have evaluated the brain functional changes associated with disease-modifying therapies (DMTs) in multiple sclerosis (MS), though none used a composite measure of clinical and MRI outcomes to evaluate DMT-related brain functional connectivity (FC) measures predictive of short-term...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piervincenzi, Claudia, Petsas, Nikolaos, De Giglio, Laura, Carmellini, Maurizio, Giannì, Costanza, Tommasin, Silvia, Pozzilli, Carlo, Pantano, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973271/ https://www.ncbi.nlm.nih.gov/pubmed/33746887 http://dx.doi.org/10.3389/fneur.2021.632917

Ejemplares similares

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

The Role of fMRI in the Assessment of Neuroplasticity in MS: A Systematic Review
por: Laura, De Giglio, et al.
Publicado: (2018)

Erratum to “The Role of fMRI in the Assessment of Neuroplasticity in MS: A Systematic Review”
por: De Giglio, Laura, et al.
Publicado: (2019)

Neuroimaging markers of Alice in Wonderland syndrome in patients with migraine with aura
por: Mastria, Giulio, et al.
Publicado: (2023)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

Parkinsonism Is Associated with Altered SMA-Basal Ganglia Structural and Functional Connectivity in Frontotemporal Degeneration
por: Piervincenzi, Claudia, et al.
Publicado: (2023)

Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis
por: Tommasin, Silvia, et al.
Publicado: (2021)

Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques
por: Taloni, Alessandro, et al.
Publicado: (2022)

Cortico-Subcortical White Matter Bundle Changes in Cervical Dystonia and Blepharospasm
por: Giannì, Costanza, et al.
Publicado: (2023)

White matter alterations in drug-naïve children with Tourette syndrome and obsessive-compulsive disorder
por: Bharti, Komal, et al.
Publicado: (2022)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

The Role of fMRI to Assess Plasticity of the Motor System in MS
por: Pantano, Patrizia, et al.
Publicado: (2015)

Resting-State fMRI in MS: General Concepts and Brief Overview of Its Application
por: Sbardella, Emilia, et al.
Publicado: (2015)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
por: Jaklin, Andreas K., et al.
Publicado: (2021)

Abnormal Resting-State Functional Connectivity in Progressive Supranuclear Palsy and Corticobasal Syndrome
por: Bharti, Komal, et al.
Publicado: (2017)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2023)

NEDA—NEutron Detector Array
por: Valiente-Dobón, J J, et al.
Publicado: (2019)

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach
por: Bunul, Sena Destan, et al.
Publicado: (2023)

Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients
por: Sbardella, Emilia, et al.
Publicado: (2013)

Diagnosis and Management of Fingolimod-Associated Macular Edema
por: Wang, Chunjiang, et al.
Publicado: (2022)

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod
por: Maass, Fabian, et al.
Publicado: (2021)

Structural Cerebellar Abnormalities and Parkinsonism in Patients with 22q11.2 Deletion Syndrome
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

The Cerebellum in Drug-naive Children with Tourette Syndrome and Obsessive–Compulsive Disorder
por: Tikoo, Sankalp, et al.
Publicado: (2021)

Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis
por: Rotstein, Dalia, et al.
Publicado: (2022)

DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications
por: Sbardella, Emilia, et al.
Publicado: (2013)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2013)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vla7a882k80bklt35pokalsj56